trending Market Intelligence /marketintelligence/en/news-insights/trending/r2tg2havr69xw2reii4rbg2 content esgSubNav
In This List

J&J to stop lung, blood cancer trials for Darzalex combo treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


J&J to stop lung, blood cancer trials for Darzalex combo treatment

Johnson & Johnson will end two clinical trials for Darzalex — one for lung cancer and another for blood cancer — following a review by a data monitoring committee.

The committee recommended the termination of a phase 1b/2 study of Darzalex plus Roche Holding AG's Tecentriq in patients with previously treated non-small cell lung cancer after determining that the combination did not provide benefits over Tecentriq alone.

Darzalex is also known as daratumumab, while Tecentriq is also known as atezolizumab.

The committee also found an increase in mortality-related events among patients in the combination arm of the study, which is called Callisto/LUC2001.

Based on the findings, J&J unit Janssen Biotech Inc. decided to discontinue another study, a phase 1 trial called MMY2036. This study was evaluating Darzalex plus JNJ-63723283 in patients with multiple myeloma.

The LUC2001 study included 98 patients while the MMY2036 study includes up to 386 patients.

Janssen said it informed health authorities about the developments and reached out to its partner companies to discuss stopping enrollment and dosing while it further evaluates the data.

Janssen acquired exclusive worldwide rights to daratumumab from Genmab A/S in 2012. The drug is undergoing multiple phase 3 clinical studies, and has received U.S. Food and Drug Administration approval to treat multiple myeloma, along with two breakthrough therapy designations.